Contrary to these studies, we have shown that more potent AKR1C3 inhibitors with greater isoform selectivity reverse drug resistance to etoposide11, daunorubicin, and cytarabine in AML cells and patient-derived T-ALL cells10. The gene discussed is AKR1C3; the disease is acute myeloid leukemia.